Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
memo - Magazine of European Medical Oncology
Published in: memo - Magazine of European Medical Oncology 1/2024

Open Access 13-10-2023 | Vaccination | special report

Cellular and humoral responses to fourth SARS-CoV-2 vaccination in a real-life cohort of patients with cancer

Authors: Julia M. Berger, MD, Pia Gattinger, PhD, Maximilian J. Mair, MD, PhD, Anna S. Berghoff, MD, PhD, Rudolf Valenta, MD, Matthias Preusser, MD

Published in: memo - Magazine of European Medical Oncology | Issue 1/2024

Login to get access

Summary

This study assessed cellular and humoral responses to the fourth dose of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) vaccines in patients with malignant diseases. Even though, clear indications of humoral, cellular, or combined response was evident in most patients undergoing active treatment, high intra- and interpatient heterogeneity in response patterns was observed.
Literature
1.
Mairhofer M, Kausche L, Kaltenbrunner S, Ghanem R, Stegemann M, Klein K, et al. Humoral and cellular immune responses in SARS-CoV‑2 mRNA-vaccinated patients with cancer. Cancer Cell. 2021;39:1171–2.CrossRefPubMedPubMedCentral
2.
3.
Debie Y, Van Audenaerde JRM, Vandamme T, Croes L, Teuwen L‑A, Verbruggen L, et al. Humoral and cellular immune responses against SARS-CoV‑2 after third dose BNT162b2 following double-dose vaccination with BNT162b2 versus ChAdox1 in patients with cancer. Clin Cancer Res. 2022; https://​doi.​org/​10.​1158/​1078-0432.​CCR-22-2185.CrossRef
4.
Gattinger P, Niespodziana K, Stiasny K, Sahanic S, Tulaeva I, Borochova K, et al. Neutralization of SARS-CoV‑2 requires antibodies against conformational receptor-binding domain epitopes. Allergy. 2022;77(1):230–42.CrossRefPubMed
Metadata
Title
Cellular and humoral responses to fourth SARS-CoV-2 vaccination in a real-life cohort of patients with cancer
Authors
Julia M. Berger, MD
Pia Gattinger, PhD
Maximilian J. Mair, MD, PhD
Anna S. Berghoff, MD, PhD
Rudolf Valenta, MD
Matthias Preusser, MD
Publication date
13-10-2023
Publisher
Springer Vienna
Published in
memo - Magazine of European Medical Oncology / Issue 1/2024
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-023-00916-y

Other articles of this Issue 1/2024

memo - Magazine of European Medical Oncology 1/2024 Go to the issue

short review

(Neo)adjuvant approaches in lung cancer—paving the road to a cure

short review

Management of oligometastatic prostate cancer

short review

Cancer of unknown primary—state of the art

short review

Total neoadjuvant therapy for each local advanced rectal cancer?

editorial

OeGHO annual meeting 2023—best of oncology

editorial

“Navigating the evolving landscape of cancer treatment: a triad of progress”
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits